LEADER 00930nam 2200313 450 001 9910472260503321 005 20210511115836.0 010 $a978-88-214-4787-7 100 $a20210511d2018----km-y0itay50------ba 101 1 $aita$ceng 102 $aIT 105 $aa-------001yy 200 1 $aManuale di pediatria$fTom Lissauer, Will Carroll$gedizione italiana a cura di Carlo Catassi ... [et al.] 205 $a5. ed. 210 $aMilano$cEdra$d2018 215 $aXVIII, 590 p.$cill.$d28 cm 610 0 $aPediatria$aManuali 700 1$aLissauer,$bTom$0764923 701 1$aCarroll,$bWill$0793241 702 1$aCatassi,$bCarlo 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a9910472260503321 952 $a90 R 14a 81$b211/2021$fFMEBC 952 $a90 R 14a 82$b212/2021$fFMEBC 952 $a90 R 14a 83$b213/2021$fFMEBC 959 $aFMEBC 996 $aManuale di pediatria$91774183 997 $aUNINA LEADER 06756nam 2201933z- 450 001 9910557623503321 005 20210501 035 $a(CKB)5400000000045180 035 $a(oapen)https://directory.doabooks.org/handle/20.500.12854/69075 035 $a(oapen)doab69075 035 $a(EXLCZ)995400000000045180 100 $a20202105d2020 |y 0 101 0 $aeng 135 $aurmn|---annan 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aTargeting STAT3 and STAT5 in Cancer 210 $aBasel, Switzerland$cMDPI - Multidisciplinary Digital Publishing Institute$d2020 215 $a1 online resource (578 p.) 311 08$a3-03943-036-X 311 08$a3-03943-037-8 330 $aEvery minute, 34 new patients are diagnosed with cancer globally. Although over the past 50 years treatments have improved and survival rates have increased dramatically for several types of cancers, many remain incurable. Several aggressive types of blood and solid cancers form when mutations occur in a critical cellular signaling pathway, the JAK-STAT pathway; (Janus Kinase-Signal Transducer and Activator of Transcription). Currently, there are no clinically available drugs that target the oncogenic STAT3/5 proteins in particular or their Gain of Function hyperactive mutant products. Here, we summarize targeting approaches on STAT3/5, as the field moves towards clinical applications as well as we illuminate on upstream or downstream JAK-STAT pathway interference with kinase inhibitors, heat shock protein blockers or changing nuclear import/export processes. We cover the design paradigms and medicinal chemistry approaches to illuminate progress and challenges in understanding the pleiotropic role of STAT3 and STAT5 in oncogenesis, the microenvironment, the immune system in particular, all culminating in a complex interplay towards cancer progression. 606 $aBiology, life sciences$2bicssc 606 $aResearch & information: general$2bicssc 610 $aADAM17 610 $aadoptive T cell therapy 610 $aAKT 610 $aandrogens 610 $aapoptosis 610 $aautoimmune disease 610 $aautosomal-dominant hyper IgE syndrome 610 $aBone Marrow Failure Syndromes 610 $abreast cancer 610 $acancer 610 $acancer models 610 $acancer progression 610 $acancer-stem cell 610 $aCD38 610 $aCD4+ T cells 610 $aCD8+ T cells 610 $acell cycle 610 $acell hierarchy 610 $achaperones 610 $achemotherapy resistance 610 $acirrhosis 610 $acolon cancer 610 $acompanion animals 610 $acomparative oncology 610 $acytokine 610 $acytokine receptor signaling 610 $adynamic programming 610 $aendoplasmic reticulum (ER) stress 610 $aepidermal growth factor receptor (EGF-R) 610 $aERK1/2 610 $aescape mechanisms 610 $again-of-function mutation 610 $aglioblastoma 610 $aglioma 610 $agrowth hormone insensitivity syndrome 610 $aheat shock proteins 610 $ahedging 610 $ahematopoietic cancers 610 $ahepatitis C virus (HCV) 610 $ahepatocellular carcinoma (HCC) 610 $ahepatocyte nuclear factor 4 alpha (HNF4A) 610 $aimmune check point 610 $aimmune suppression 610 $aimmunosuppression 610 $aimmunotherapy 610 $ainflammation 610 $ainflammation associated cancer 610 $ainflammatory hepatocellular adenomas 610 $ainterleukin-6 610 $aJAK 610 $aJAK family of protein tyrosine kinases 610 $aJAK2 V617F 610 $aknockout 610 $alipopolyplex 610 $alung cancer 610 $alymphocytes 610 $alymphoma 610 $aM2 macrophages 610 $amelanoma 610 $ameta-analysis 610 $ametalloprotease 610 $ametastasis 610 $amicroRNA-122 (miR-122) 610 $amitochondria 610 $aMPN 610 $amTOR 610 $amultiple myeloma 610 $amutations 610 $amyeloid cells 610 $amyeloid leukemia 610 $an/a 610 $ananoparticle 610 $aneoplastic stem cells 610 $aNGS 610 $aNK cells 610 $anuclear factor erythroid 2-related factor 2 (NRF2) 610 $anuclear pore complex 610 $anuclear transport receptors 610 $anucleocytoplasmic shuttling 610 $aovarian cancer 610 $aoxidative stress (OS) 610 $aPD-L1 610 $aPEI 610 $apharmacological inhibitor 610 $apharmacological inhibitors 610 $apolyethylenimine 610 $apost-decision state variable 610 $aprolactin 610 $aproliferation 610 $aprostate cancer 610 $aRHOA 610 $arisk management 610 $aS3I-1757 610 $aSH2 domain 610 $ashedding 610 $asignal transducer and activator of transcription 610 $asignal transducer and activator of transcription 3 (STAT3) 610 $asiRNA delivery 610 $asiRNA/RNAi 610 $asmall-molecule inhibitors 610 $asolid cancers 610 $astabilization 610 $aSTAT 610 $aSTAT transcription factors 610 $aSTAT3 610 $aSTAT3 inhibitor XIII 610 $aSTAT5 610 $aSTAT5 signaling 610 $aSTAT5B signaling 610 $astem/progenitor cells 610 $astemness 610 $aT-cell large granular lymphocytic leukemia 610 $aT-cell leukemia 610 $aT-cell prolymphocytic leukemia 610 $aT-cells 610 $aT-PLL 610 $atargeted therapy 610 $atargeting 610 $atherapeutic targeting 610 $atherapy resistance 610 $atrans-signaling 610 $atransaction costs 610 $atumor microenvironment 610 $atumor necrosis factor alpha (TNF?) 610 $atumor suppression 610 $atumor-associated macrophages 610 $atumor-immune cell interactions 610 $atumorigenesis 610 $atyrosine kinase 2 610 $aunfolded protein response (UPR) 615 7$aBiology, life sciences 615 7$aResearch & information: general 702 $aGunning$b Patrick$4edt 702 $aKeseru?$b G. M$4edt 702 $aMoriggl$b Richard$4edt 906 $aBOOK 912 $a9910557623503321 996 $aTargeting STAT3 and STAT5 in Cancer$93020509 997 $aUNINA